Analysts Recommendations: Eli Lilly and Company (NYSE:LLY)

Over the past five trading sessions it is 0.29%; 7.09% for the month; 4.74% for the last quarter; -12.94% for the past six-months; and -16.28% for the last 12 months.

In the past 5 years, the stock showed growth of -1.25% per annum. Strategic Financial Group LLC increased its stake in shares of Eli Lilly and by 0.5% in the third quarter.

Many analysts are providing their Estimated Earnings analysis for Eli Lilly and Company and for the current quarter 14 analysts have projected that the stock could give an Average Earnings estimate of $0.96/share. Institutional investors and hedge funds own 75.15% of the company's stock.

The results included 83% of patients who obtained a Psoriasis Area Severity Index (PASI) score of 90. Latest closing price was 7.15% above its 50-day moving average and 8.62% above its 200-day moving average. For LLY, the company now has $4.58 Billion of cash on the books, which is offset by $1.94 Billion current liabilities. Looking at the stock's movement on the chart, Eli Lilly and Company recorded a 52-week high of $84.28. Eli Lilly and had a return on equity of 24.74% and a net margin of 12.90%. According to these analysts, the Low Revenue Estimate for Eli Lilly and Company is 5.1 Billion and the High Revenue Estimate is 5.33 Billion. During the same period in the previous year, the business earned $0.78 earnings per share. The company's revenue was up 7.2% on a year-over-year basis. The company is estimating to achieve earnings per share (EPS) growth of 14.10% in this year and the earnings per share (EPS) growth expected to be 6.90% in the next year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 10th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.48%. The ex-dividend date is Monday, February 13th. Eli Lilly and Company's payout ratio is 88.70%.

This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another domain, it was copied illegally and republished in violation of United States & worldwide copyright & trademark legislation. According to a research note disclosed on Sep 08, 2016, analysts at JP Morgan have upped their rating on these shares from Neutral to Overweight.

Eli Lilly and Company (LLY) is an interesting player in the Healthcare space, with a focus on Drug Manufacturers - Major. The rating firm issued a Overweight rating to this company in a research note released on Dec 16, 2016. Tredje AP fonden's holdings in Eli Lilly and Company were worth $13,467,000 at the end of the most recent reporting period. Analyst Recommendation is an outlook of a stock-market analyst on a stock. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. BMO Capital Markets restated a "buy" rating and set a $94.00 target price on shares of Eli Lilly and Company in a research report on Monday, October 3rd. The shares were sold at an average price of $80.27, for a total transaction of $18,462,100.00. As a company's earnings per share being to rise, so does their market value per share. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

In other news, SVP Susan Mahony sold 20,242 shares of the firm's stock in a transaction dated Friday, December 16th. The shares were purchased at an average cost of $71.85 per share, with a total value of $35,925.00. Swiss National Bank now owns 3,249,843 shares of the company's stock valued at $255,925,000 after buying an additional 196,000 shares in the last quarter. The disclosure for this purchase can be found here. A company with a lower ratio, on the other hand, is usually an indication of poor current and future performance.

  • Zachary Reyes